PT Kalbe Farma Tbk is a drug manufacturing company that focuses on prescription pharmaceuticals, over-the-counter drugs, energy drinks, and nutrition products... Show more
The 50-day moving average for PTKFF moved above the 200-day moving average on August 13, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Aroon Indicator entered an Uptrend today. In of 90 cases where PTKFF Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.169) is normal, around the industry mean (9.441). P/E Ratio (20.962) is within average values for comparable stocks, (23.751). Projected Growth (PEG Ratio) (1.804) is also within normal values, averaging (1.853). Dividend Yield (0.023) settles around the average of (0.027) among similar stocks. P/S Ratio (2.145) is also within normal values, averaging (3.410).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. PTKFF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PTKFF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 80, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Industry PharmaceuticalsMajor
A.I.dvisor tells us that PTKFF and SNPHF have been poorly correlated (+2% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PTKFF and SNPHF's prices will move in lockstep.
Ticker / NAME | Correlation To PTKFF | 1D Price Change % | ||
---|---|---|---|---|
PTKFF | 100% | N/A | ||
SNPHF - PTKFF | 2% Poorly correlated | N/A | ||
OTSKY - PTKFF | 1% Poorly correlated | +0.38% | ||
OTSKF - PTKFF | 0% Poorly correlated | N/A | ||
RCDTF - PTKFF | 0% Poorly correlated | N/A | ||
SNPHY - PTKFF | -0% Poorly correlated | +3.82% | ||
More |